These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

148 related articles for article (PubMed ID: 38555022)

  • 1. New conjugates based on N4-hydroxycytidine with more potent antiviral efficacy in vitro than EIDD-2801 against SARS-CoV-2 and other human coronaviruses.
    Siniavin AE; Gushchin VA; Shastina NS; Darnotuk ES; Luyksaar SI; Russu LI; Inshakova AM; Shidlovskaya EV; Vasina DV; Kuznetsova NA; Savina DM; Zorkov ID; Dolzhikova IV; Sheremet AB; Logunov DY; Zigangirova NA; Gintsburg AL
    Antiviral Res; 2024 May; 225():105871. PubMed ID: 38555022
    [TBL] [Abstract][Full Text] [Related]  

  • 2. An orally bioavailable broad-spectrum antiviral inhibits SARS-CoV-2 in human airway epithelial cell cultures and multiple coronaviruses in mice.
    Sheahan TP; Sims AC; Zhou S; Graham RL; Pruijssers AJ; Agostini ML; Leist SR; Schäfer A; Dinnon KH; Stevens LJ; Chappell JD; Lu X; Hughes TM; George AS; Hill CS; Montgomery SA; Brown AJ; Bluemling GR; Natchus MG; Saindane M; Kolykhalov AA; Painter G; Harcourt J; Tamin A; Thornburg NJ; Swanstrom R; Denison MR; Baric RS
    Sci Transl Med; 2020 Apr; 12(541):. PubMed ID: 32253226
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Molnupiravir and Its Antiviral Activity Against COVID-19.
    Tian L; Pang Z; Li M; Lou F; An X; Zhu S; Song L; Tong Y; Fan H; Fan J
    Front Immunol; 2022; 13():855496. PubMed ID: 35444647
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Synthesis and Antiviral Activity of Novel β-D-N4-Hydroxycytidine Ester Prodrugs as Potential Compounds for the Treatment of SARS-CoV-2 and Other Human Coronaviruses.
    Darnotuk ES; Siniavin AE; Shastina NS; Luyksaar SI; Inshakova AM; Bondareva NE; Zolotov SA; Lubenec NL; Sheremet AB; Logunov DY; Zigangirova NA; Gushchin VA; Gintsburg AL
    Pharmaceuticals (Basel); 2023 Dec; 17(1):. PubMed ID: 38256869
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Synthesis and anti-SARS-CoV-2 evaluation of lipid prodrugs of β-D-N
    Wen ZH; Wang MM; Li LY; Herdewijn P; Snoeck R; Andrei G; Liu ZP; Liu C
    Bioorg Chem; 2023 Jun; 135():106527. PubMed ID: 37031504
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Small-Molecule Antiviral β-d-
    Agostini ML; Pruijssers AJ; Chappell JD; Gribble J; Lu X; Andres EL; Bluemling GR; Lockwood MA; Sheahan TP; Sims AC; Natchus MG; Saindane M; Kolykhalov AA; Painter GR; Baric RS; Denison MR
    J Virol; 2019 Dec; 93(24):. PubMed ID: 31578288
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Repurposing Molnupiravir for COVID-19: The Mechanisms of Antiviral Activity.
    Yip AJW; Low ZY; Chow VTK; Lal SK
    Viruses; 2022 Jun; 14(6):. PubMed ID: 35746815
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pharmacokinetics of ß-d-N4-Hydroxycytidine, the Parent Nucleoside of Prodrug Molnupiravir, in Nonplasma Compartments of Patients With Severe Acute Respiratory Syndrome Coronavirus 2 Infection.
    FitzGerald R; Dickinson L; Else L; Fletcher T; Hale C; Amara A; Walker L; Penchala SD; Lyon R; Shaw V; Greenhalf W; Bullock K; Lavelle-Langham L; Reynolds H; Painter W; Holman W; Ewings S; Griffiths G; Khoo S
    Clin Infect Dis; 2022 Aug; 75(1):e525-e528. PubMed ID: 35271729
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Molnupiravir promotes SARS-CoV-2 mutagenesis via the RNA template.
    Gordon CJ; Tchesnokov EP; Schinazi RF; Götte M
    J Biol Chem; 2021 Jul; 297(1):100770. PubMed ID: 33989635
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Therapeutically administered ribonucleoside analogue MK-4482/EIDD-2801 blocks SARS-CoV-2 transmission in ferrets.
    Cox RM; Wolf JD; Plemper RK
    Nat Microbiol; 2021 Jan; 6(1):11-18. PubMed ID: 33273742
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Molnupiravir inhibits SARS-CoV-2 variants including Omicron in the hamster model.
    Rosenke K; Okumura A; Lewis MC; Feldmann F; Meade-White K; Bohler WF; Griffin A; Rosenke R; Shaia C; Jarvis MA; Feldmann H
    JCI Insight; 2022 Jul; 7(13):. PubMed ID: 35579953
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Molnupiravir: A lethal mutagenic drug against rapidly mutating severe acute respiratory syndrome coronavirus 2-A narrative review.
    Masyeni S; Iqhrammullah M; Frediansyah A; Nainu F; Tallei T; Emran TB; Ophinni Y; Dhama K; Harapan H
    J Med Virol; 2022 Jul; 94(7):3006-3016. PubMed ID: 35315098
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Efficacy of late-onset antiviral treatment in immunocompromised hosts with persistent SARS-CoV-2 infection.
    Lieber CM; Kang H-J; Sobolik EB; Sticher ZM; Ngo VL; Gewirtz AT; Kolykhalov AA; Natchus MG; Greninger AL; Suthar MS; Plemper RK
    J Virol; 2024 Sep; 98(9):e0090524. PubMed ID: 39207133
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Viral polymerase binding and broad-spectrum antiviral activity of molnupiravir against human seasonal coronaviruses.
    Wang Y; Li P; Solanki K; Li Y; Ma Z; Peppelenbosch MP; Baig MS; Pan Q
    Virology; 2021 Dec; 564():33-38. PubMed ID: 34619630
    [TBL] [Abstract][Full Text] [Related]  

  • 15. SARS-CoV-2 infection is effectively treated and prevented by EIDD-2801.
    Wahl A; Gralinski LE; Johnson CE; Yao W; Kovarova M; Dinnon KH; Liu H; Madden VJ; Krzystek HM; De C; White KK; Gully K; Schäfer A; Zaman T; Leist SR; Grant PO; Bluemling GR; Kolykhalov AA; Natchus MG; Askin FB; Painter G; Browne EP; Jones CD; Pickles RJ; Baric RS; Garcia JV
    Nature; 2021 Mar; 591(7850):451-457. PubMed ID: 33561864
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Plitidepsin, an inhibitor of the cell elongation factor eEF1a, and molnupiravir an analogue of the ribonucleoside cytidine, two new chemical compounds with intense activity against SARS-CoV-2].
    Reina J
    Rev Esp Quimioter; 2021 Oct; 34(5):402-407. PubMed ID: 33902254
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Transfer and biotransformation of the COVID-19 prodrug molnupiravir and its metabolite β-D-N4-hydroxycytidine across the blood-placenta barrier.
    Chang CH; Peng WY; Lee WH; Lin TY; Yang MH; Dalley JW; Tsai TH
    EBioMedicine; 2023 Sep; 95():104748. PubMed ID: 37544201
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Molnupiravir maintains antiviral activity against SARS-CoV-2 variants and exhibits a high barrier to the development of resistance.
    Strizki JM; Gaspar JM; Howe JA; Hutchins B; Mohri H; Nair MS; Kinek KC; McKenna P; Goh SL; Murgolo N
    Antimicrob Agents Chemother; 2024 Jan; 68(1):e0095323. PubMed ID: 38047645
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Oxidative DNA Damage by N4-hydroxycytidine, a Metabolite of the SARS-CoV-2 Antiviral Molnupiravir.
    Kobayashi H; Mori Y; Ahmed S; Hirao Y; Kato S; Kawanishi S; Murata M; Oikawa S
    J Infect Dis; 2023 Apr; 227(9):1068-1072. PubMed ID: 36461940
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparative docking and molecular dynamics studies of molnupiravir (EIDD-2801): implications for novel mechanisms of action on influenza and SARS-CoV-2 protein targets.
    Istifli ES; Okumus N; Sarikurkcu C; Kuhn ER; Netz PA; Tepe AS
    J Biomol Struct Dyn; 2024 Sep; 42(15):8202-8214. PubMed ID: 37811782
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.